SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Guideline addresses benefits and harms of sodium-glucose cotransporter 2 inhibitors & glucagon-like peptide 1 receptor agonists when added to usual care (lifestyle interventions and/or other diabetes drugs) in adults with type 2 diabetes at different risk for CV & kidney outcomes
Source:
British Medical Journal
SPS commentary:
Editorial discusses recommendations for use of SGLT-2 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists and their role in current guidelines. It concludes need for shared decision making for individualised therapy to optimise CV and renal health.